• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACELYRIN, INC. - Common Stock (NQ:SLRN)

2.270 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ACELYRIN, INC. - Common Stock

< Previous 1 2 3 4 5 Next >
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
May 13, 2025
From ACELYRIN, INC.
Via GlobeNewswire
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
May 06, 2025
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today 
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
May 01, 2025
From ACELYRIN, INC.
Via GlobeNewswire
Alumis and ACELYRIN Announce Amended Merger Agreement
April 21, 2025
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
April 16, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders
April 07, 2025
From Halper Sadeh LLC
Via GlobeNewswire
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
March 13, 2025
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
March 04, 2025
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
March 04, 2025
From ACELYRIN, INC.
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, TGI, PTMN, SLRN on Behalf of Shareholders
February 21, 2025
From Halper Sadeh LLC
Via GlobeNewswire
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
February 20, 2025
From ACELYRIN, INC.
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPG, SLRN, PTMN, HEES on Behalf of Shareholders
February 18, 2025
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PLYA, SLRN, NVRO, AMPS on Behalf of Shareholders
February 10, 2025
From Halper Sadeh LLC
Via GlobeNewswire
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
February 10, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, TGI, PTMN on Behalf of Shareholders
February 10, 2025
From Halper Sadeh LLC
Via GlobeNewswire
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
February 06, 2025
From Halper Sadeh LLC
Via Business Wire
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
February 06, 2025
From Ademi & Fruchter LLP
Via Business Wire
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
February 06, 2025
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
January 06, 2025
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
January 02, 2025
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
December 10, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
November 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
November 06, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
October 16, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
September 19, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
September 10, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
August 22, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
August 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
August 06, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
June 05, 2024
From ACELYRIN, INC.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap